[Comparative study of adriamycin, epirubicin and mitoxantrone in cancer of the breast. Review of the literature].
An overview of all published randomized trials which compared mitoxantrone or epirubicine to adriamycin was performed to analyse tolerance, toxicity and efficacy of these drugs, related to adriamycin. Mitoxantrone confirms its better tolerance: nausea and vomiting are less frequent (P < 10(-9)) and alopecia less intensive (P < 10(-9)). There is a significant decrease in cardiotoxicity occurrence with mitoxantrone (P < 0.01) but a significantly higher degree of leucopenia (P < 10(-4)). As far a response rate is concerned, mitoxantrone is somewhat less effective than adriamycin (P < 0.001). As compared to adriamycin, epirubicine does not reduce side effects incidence, nevertheless, their intensity is less important: nausea and vomiting (P < 0.04) and alopecia (P < 0.01). Leucopenia is less frequent following epirubicine administration as compared to adriamycin, documented course by course (P < 0.01) or on the overall treatment (P < 0.01). Epirubicine is noted to be less cardiotoxic than adriamycin (P = 0.001) with a decreased incidence of heart failures (P < 0.05). No difference can be observed in response rate between these two treatments, for objective as well as for complete responses.
Delozier
T
T
Service de radiothérapie, centre François-Baclesse, Caen, France.
Vernhes
J C
JC
D000505:Alopecia / Q000139:chemically induced; D004317:Doxorubicin / Q000009:adverse effects*; D015251:Epirubicin / Q000009:adverse effects*; D006321:Heart / Q000187:drug effects; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008942:Mitoxantrone / Q000009:adverse effects*; D009325:Nausea / Q000139:chemically induced; D016032:Randomized Controlled Trials as Topic
D015251:Epirubicin; D004317:Doxorubicin; D008942:Mitoxantrone
Etude comparative de l'adriamycine, l'épirubicine et la mitoxantrone dans le cancer du sein. Revue de la littérature.